ProfileGDS5678 / 1431162_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 71% 69% 72% 71% 72% 72% 70% 71% 71% 72% 66% 74% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3816270
GSM967853U87-EV human glioblastoma xenograft - Control 24.4721971
GSM967854U87-EV human glioblastoma xenograft - Control 34.2910269
GSM967855U87-EV human glioblastoma xenograft - Control 44.6265572
GSM967856U87-EV human glioblastoma xenograft - Control 54.4174471
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5458172
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5423872
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3860270
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4511871
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4515471
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6115372
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9999766
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7709974
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5842172